

Published Clinical References

QuantiFERON®-CMV

Independent published papers:

QuantiFERON®-CMV - evaluation of clinical utility

1. Walker S, et al. (2007) Ex-vivo monitoring of human cytomegalovirus-specific CD8+ T-Cell responses using QuantiFERON®-CMV. *Transpl Infect Dis*; **9**:165-170.
2. Singh KP et al. (2007) Human cytomegalovirus (HCMV)-specific CD8+ T-Cell responses are reduced in HIV-infected individuals with a history of HCMV disease despite CD4+ T-Cell recovery. *Clin Immunol* **124**: 200-206.
3. Westall GP, et al. (2008) Linking CMV Serostatus to Episodes of CMV Reactivation Following Lung Transplantation by Measuring CMV-Specific CD8+ T-Cell Immunity. *Am J Transplant*. **8**:1749-1754.
4. Kumar D, et al. (2009) Cell-Mediated Immunity to Predict Cytomegalovirus Disease in High-Risk Solid Organ Transplant Recipients. *Am J Transplant*. **9**: 1214-1222.
5. Fleming T, et al. (2010) Ex Vivo Monitoring of Human Cytomegalovirus-Specific CD8+ T-Cell Responses Using the QuantiFERON®-CMV Assay in Allogeneic Hematopoietic Stem Cell Transplant Recipients attending an Irish Hospital. *Journal of Medical Virology* **82**: 433-440.
6. Lochmanova AI, et al. (2010) QuantiFERON®-CMV Test in Prediction of Cytomegalovirus Infection after Kidney Transplantation. *Transplantation Proceedings*. **42(9)**: 3574-3577.
7. Lisboa LF, et al. (2012) Clinical Utility of Cytomegalovirus Cell-Mediated Immunity in Transplant Recipients with Cytomegalovirus Viremia. *Transplantation* **93**: 195-200.
8. Clari MA, et al. (2012) Performance of the QuantiFERON®-cytomegalovirus (CMV) Assay for Detecting and Estimating the Magnitude and Functionality of the CMV-Specific IFN- γ CD8+ T-Cell Response in Allogeneic Stem Cell Transplant Recipients. Published online ahead of print on 29 February 2012. *Clin. Vaccine Immunol*. doi:10.1128/CVI.05633-111
9. Weseslindtner L et al. (2012) Prospective Analysis of Human Cytomegalovirus DNAemia and Specific CD8+ T-Cell Responses in Lung Transplant Recipients. *Am J Transplant*. **12(8)**: 2172-80.
10. Gayoso I, et al. (2013) Clinical Factors Influencing Phenotype of HCMV-Specific CD8+ T Cells and HCMV-Induced Interferon-Gamma Production after Allogeneic Stem Cells Transplantation. *Clin Dev Immunol*. 2013:347213. doi: 10.1155/2013/347213. Epub 2013 Feb 2.
11. Cantisán S, et al. (2013) Pre-Transplant Interferon- γ secretion by CMV-specific CD8+ T-cells informs the risk of CMV replication after transplantation. *Am J Transplant*. 2013 Mar;**13(3)**:738-45.
12. Manuel O, et al. (2013) Assessment of cytomegalovirus specific cell-mediated immunity for the prediction of cytomegalovirus disease in high-risk solid-organ transplant recipients: a multicenter cohort study. *Clin Infect Dis*. 2013 Mar;**56(6)**:817-24.
13. Weseslindtner L et al. (2013). Association of human cytomegalovirus DNAemia and specific granzyme B responses in lung transplant recipients. *Clin Exp Immunol*. Apr 22. doi: 10.1111/cei.12123. [Epub ahead of print]

14. Russell AS, et al. (2013) QuantiFERON testing for cell-mediated immunity to cytomegalovirus in patients with rheumatoid arthritis receiving abatacept and other DMARD therapy. *Clinical Rheumatology*. Published on line June 11, 2013.
15. Abate D, et al. (2013) Comparison of cytomegalovirus (CMV) enzyme-linked immunosorbent spot and CMV quantiferon gamma interferon-releasing assays in assessing risk of CMV infection in kidney transplant recipients. *Journal of Clinical Microbiology* 2013 Aug, **51(8)**: 2501-7

Current consensus guidelines on the management of cytomegalovirus in solid organ transplantation

1. Kotton CN, et al. (2010) International Consensus Guidelines on the Management of Cytomegalovirus in Solid Organ Transplantation. *Transplantation*. **89**: 779-795.
2. Torre-Cisneros J et al. (2011) GESITRA-SEIMC/REIPI Recommendations for the management of cytomegalovirus infection in solid-organ transplant patients. *Enferm Infecc Microbiol Clin*. **29(10)**: 735-758.
3. Kotton CN, et al. (2013) Updated International Consensus Guidelines on the Management of Cytomegalovirus in Solid-Organ Transplantation. *Transplantation* **96**, (Jul 312013). Epub ahead of print.

Other published references in support of QuantiFERON®-CMV as a utility to measure CMV specific CMI responses

1. Danziger-Isakov L, Heeger PS. (2009) Clinical utility of measuring T-Cell immunity to CMV in transplant recipients. *Am J Transplant*. **9**: 987-988.
2. Crough T, Khanna R. (2009) Immunobiology of human cytomegalovirus: from bench to bedside. *Clin Microbiol Rev*. **22(1)**: 76-98.
3. Torre-Cisneros J. (2009) Toward the Individualization of Cytomegalovirus Control after Solid-Organ Transplantation: The Importance of the "Individual Pathogenic Balance". *Clin Infect Dis*. **49(8)**: 1167-8.
4. Kumar D, Humar A. (2010) Transplantation: Cytomegalovirus prophylaxis: How long is enough? *Nat Rev Nephrol*. **6(1)**: 13-4.
5. Weclawiaka H, et al. (2010) Cytomegalovirus effects in solid organ transplantation and place of antiviral prophylaxis. *Néphrologie & Thérapeutique*. **6(6)**: 505-512 (in French).
6. Kotton CN. (2010) Management of cytomegalovirus infection in solid organ transplantation. *Nat. Rev. Nephrol*. Advance online publication 26 October 2010; doi:10.1038/nrneph. 2010.
7. Dumitru IM, Rugina S, Dumitru E, Cernat RC, Diaconu S, Maxim Mitroi C. (2010) Immunological diagnosis of CMV infection in HIV-infected patients. *J Int AIDS Soc*. **13(Suppl 4)**: P192.
8. Giulieri S, Manuel O. (2011) QuantiFERON®-CMV assay for the assessment of cytomegalovirus cell mediated immunity. *Expert Rev. Mol. Diagn*. **11 (1)**: 17-25.
9. Cantisán Bohórquez S, Navarro Ortega D. (2011) Immunological monitoring strategies for cytomegalovirus infection. Immune-based therapies. *Enferm Infecc Microbiol Clin*. **Suppl 6**: 28-32. (Article in Spanish)

